Lucid Group’s Post

View organization page for Lucid Group, graphic

13,682 followers

Synetic presents an expert-backed view on the revision to Good Clinical Practice (ICH E6 R3) and the likely impact of these changes on clinical operations. Click the report below to find out more... Steve Gunnigle, Matthew McLoughlin, Neil Croft, Mary Alice Dwyer, Gabrielle Marsh, Sophie Cancemi #clinicaldevelopment  #clinicaloperations #quality #decentralizedclinicaltrials #RBQM

Steve Gunnigle

Vice President, Consulting at Synetic Life Sciences

1mo

Thanks to all involved in developing the thinking. The ICH E6 changes are welcome and now mirror some of the guidance provided by Regultory Agencies. The big change will be one of mindset, and how to maintain operational efficiencies and performance expected by the C-suite, and at the same time engaging patients in clinical trial deaign (to optimise for the patient) and providing the opportunity for underrepresented groups to take part in clinical trials.

To view or add a comment, sign in

Explore topics